HER-2 Protein Overexpression Clinical Trial
Official title:
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma
This is a single-arm, exploratory clinical study.
This is a single-arm, exploratory clinical study. Aim to explore the safety and efficacy of Vedicetuzumab combined with an immune checkpoint inhibitor (carrellizumab) and platinum-based first-line treatment for locally advanced/metastatic HER2 overexpression (IHC 2+/3+) esophageal squamous cell carcinoma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05511844 -
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT02840110 -
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
|
||
Recruiting |
NCT04692831 -
Testing a New Imaging Agent to Identify Cancer
|
Phase 1 | |
Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT03680560 -
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
|
Phase 1 | |
Completed |
NCT03613168 -
Trastuzumab in HER2-positive Biliary Tract Cancer
|
Phase 2 | |
Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT05480384 -
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
|
Phase 2 | |
Enrolling by invitation |
NCT05904730 -
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
|
Phase 1 | |
Not yet recruiting |
NCT06187506 -
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT03630809 -
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
|
Phase 2 | |
Recruiting |
NCT05170256 -
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
|
Phase 2 | |
Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04995003 -
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
|
Phase 1 | |
Suspended |
NCT04650451 -
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT04215159 -
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
|
Phase 2 | |
Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
Not yet recruiting |
NCT04179656 -
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
|
Phase 2 |